Resumen de Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non‑small‑cell lung cancers: a multicenter prospective study
Maria Arnal Rondan, A. Sánchez, David Lorente Estellés, José García Sánchez, Francisco Aparisi Aparisi, Jorge Soler López, Raquel Ten Benajes, Regina Gironés Sarrió
Purpose Concurrent chemoradiotherapy (cCRT) is the standard treatment for locally advanced and unresectable non-smallcell lung cancer. Population is aging, and Geriatric assessment (GA) has demonstrated its paper to select ft patients for active treatment and vulnerable, frail patients for interventions and/or palliative care in many histologies. Its role in locally advanced, unresectable non-small-cell lung cancer has been less explored.
Methods To assess the capability of GA to detect frail patients not suitable for active treatment, we developed this exploratory non-interventional prospective study. All patients≥70 years diagnosed with stage locally advanced and unresectable non-small-cell lung cancer were invited to undergo geriatric assessment. Secondary aims were description of population, exploring GA as prognostic factor, determination of toxicity profle and look for a frailty biomarker.
Results From June 2017 to June 2020, 51 patients were included, of whom 35% (n:18) were classifed as frail. Frail patients had less overall survival and more grade 3–4 toxicity. Exploratory results for frailty phenotype are described in the text.
Conclusions With the results of our study, we confrm that GA can detect frail patients unsuitable for treatment, with a higher risk of toxicity and less overall survival. A trend toward blood-test results for phenotype frailty can be hypothesis generation.
